Avecho Biotechnology Limited (AVEFF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avecho Biotechnology Limited (AVEFF) trades at $0.00 with AI Score 51/100 (Grade B). Avecho Biotechnology Limited specializes in innovative drug delivery systems through its patented Targeted Penetration Matrix (TPM) technology. Market cap: $10.68M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for AVEFF: AVEFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AVEFF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AVEFF: the 6 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Avecho Biotechnology Limited (AVEFF) Healthcare & Pipeline Overview
Avecho Biotechnology Limited leverages its proprietary Targeted Penetration Matrix (TPM) technology to revolutionize drug delivery across pharmaceuticals, skincare, and animal health, positioning itself as a key player in the biotechnology sector with a focus on innovative solutions.
What Is the Investment Thesis for AVEFF?
Avecho Biotechnology Limited presents a unique investment thesis driven by its proprietary TPM technology and diverse product offerings across pharmaceutical and animal health sectors. The company's gross margin stands at 60.7%, indicating strong potential for profitability as it scales operations. With ongoing collaborations, such as the study on cannabidiol for osteoarthritis, Avecho is poised to tap into the growing demand for innovative healthcare solutions. The biotechnology sector is expected to grow significantly, driven by advancements in drug delivery systems and personalized medicine. However, the company faces challenges, including a negative profit margin of -356.8%, which underscores the need for strategic execution and market penetration to achieve sustainable growth. Investors should monitor Avecho's progress in clinical trials and product launches, which are critical to its future revenue generation.
Based on FMP financials and quantitative analysis
AVEFF Key Highlights
- Market cap of $10.68M reflects a nascent stage in capital growth.
- Gross margin of 60.7% indicates strong product profitability potential.
- Negative profit margin of -356.8% highlights current operational challenges.
- Beta of 1.18 suggests a higher volatility compared to the market.
- No dividend yield, indicating a focus on reinvestment for growth.
Who Are AVEFF's Competitors?
AVEFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PFE Pfizer Inc. | $23.72 | -2.47% | 136B | 64 |
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AVEFF's Key Strengths?
- Proprietary drug delivery technology enhances product efficacy.
- Strong gross margin indicates potential for profitability.
- Diverse product offerings across multiple sectors.
What Are AVEFF's Weaknesses?
- Negative profit margin indicates current financial challenges.
- Limited employee base may restrict operational capacity.
- Dependence on collaborations for research and development.
What Could Drive AVEFF Stock Higher?
- Results from the collaboration with the Lambert Initiative on cannabidiol for osteoarthritis.
- Development of TPM/Oxymorphone and TPM/Oxycodone products.
- Expansion of non-antibiotic feed additive products in livestock markets.
What Are the Key Risks for AVEFF?
- Financial-distress signal — its Altman Z-Score of -48.82 sits in the distress zone (elevated bankruptcy risk).
- Regulatory hurdles in drug development could delay product launches.
- Financial instability due to negative profit margins may affect operations.
- Competition from larger, established biotechnology firms could impact market share.
What Are the Growth Opportunities for AVEFF?
- Growth opportunity 1: Avecho's collaboration with the Lambert Initiative at the University of Sydney to explore the efficacy of cannabidiol for osteoarthritis could open new therapeutic avenues. The global market for osteoarthritis treatments is expected to reach $8 billion by 2027, providing a significant opportunity for Avecho to capture market share through innovative solutions.
- Growth opportunity 2: The expansion of Avecho's TPM technology into the skincare market represents a lucrative avenue, as the global skincare market is projected to reach $189 billion by 2025. By leveraging its patented technology, Avecho can enhance the delivery of active ingredients in cosmetic formulations, appealing to a growing consumer base focused on efficacy and quality.
- Growth opportunity 3: Avecho's non-antibiotic feed additives for livestock health could tap into the increasing demand for sustainable animal nutrition solutions. The global animal feed market is expected to grow to $650 billion by 2027, driven by the need for enhanced feed efficiency and animal health, positioning Avecho favorably within this expanding sector.
- Growth opportunity 4: The development of TPM/Oxymorphone and TPM/Oxycodone products aligns with the rising demand for effective pain management solutions. The global pain management market is projected to reach $83 billion by 2027, offering Avecho a pathway to introduce innovative drug delivery methods that cater to this growing need.
- Growth opportunity 5: The increasing focus on personalized medicine provides Avecho with an opportunity to tailor its drug delivery systems to specific patient needs. As the global personalized medicine market is expected to exceed $2 trillion by 2025, Avecho can leverage its technology to create customized therapeutic solutions, enhancing its market position.
What Opportunities Does AVEFF Have?
- Expanding into the growing osteoarthritis treatment market.
- Leveraging TPM technology for skincare applications.
- Tapping into the increasing demand for sustainable animal health solutions.
What Threats Does AVEFF Face?
- Intense competition from established biotechnology firms.
- Regulatory hurdles in drug development and approvals.
- Market volatility affecting funding and investment opportunities.
What Are AVEFF's Competitive Advantages?
- Proprietary TPM technology provides a competitive edge in drug delivery.
- Strong research collaborations enhance credibility and innovation.
- Diverse product portfolio reduces dependence on a single market segment.
- Established relationships with academic institutions support ongoing research.
- Focus on non-antibiotic solutions aligns with market trends toward sustainability.
What Does AVEFF Do?
Founded in 1992, Avecho Biotechnology Limited, originally known as Phosphagenics Limited, is an Australian biotechnology company based in Clayton, Australia. The company specializes in developing, producing, and selling products utilizing its proprietary Targeted Penetration Matrix (TPM) drug delivery system. This innovative technology enhances the delivery of pharmaceutical products, including gels, injectables, and patches, thereby improving therapeutic efficacy. Avecho's product portfolio also includes Vital ET for cosmetic formulations and non-antibiotic feed additives aimed at enhancing livestock health and feed efficiency. The company has established collaborations, notably with the Lambert Initiative at the University of Sydney, to study the potential of topically applied cannabidiol in alleviating osteoarthritis symptoms. Avecho serves a diverse customer base across Australia, Switzerland, India, and other international markets, positioning itself as a versatile player in the healthcare sector. In May 2019, the company rebranded from Phosphagenics to Avecho Biotechnology Limited, reflecting its commitment to innovation in drug delivery and health solutions.
What Products and Services Does AVEFF Offer?
- Develops the Targeted Penetration Matrix (TPM) drug delivery system.
- Produces pharmaceutical products in various forms, including gels and patches.
- Offers Vital ET products for cosmetic formulations.
- Provides non-antibiotic feed additives for livestock health.
- Conducts research collaborations to explore innovative health solutions.
- Serves a diverse customer base across multiple international markets.
How Does AVEFF Make Money?
- Generates revenue through the sale of pharmaceutical and cosmetic products.
- Engages in research collaborations to enhance product development.
- Licenses its patented TPM technology to other companies.
- Offers consulting services in drug delivery and formulation development.
- Explores partnerships to expand market reach and product offerings.
What Industry Does AVEFF Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in drug delivery systems and increasing demand for innovative healthcare solutions. The global biotechnology market is projected to expand significantly, with a focus on personalized medicine and targeted therapies. Avecho Biotechnology Limited fits into this landscape with its unique TPM technology, which enhances the efficacy of drug delivery across various applications. The competitive landscape includes numerous biotech firms, but Avecho's focus on non-antibiotic solutions and collaborations with academic institutions provides it with a distinctive edge in addressing unmet medical needs.
Who Are AVEFF's Key Customers?
- Pharmaceutical companies seeking innovative drug delivery solutions.
- Cosmetic brands looking for effective formulation technologies.
- Livestock producers needing non-antibiotic health solutions.
- Research institutions collaborating on health-related studies.
- International markets, including Australia, Switzerland, and India.
Company Profile
Avecho Biotechnology Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Clayton, AU. The company is led by CEO Paul Gavin. AVEFF has traded publicly since 2018.
Avecho Biotechnology Limited Financial Trajectory
Avecho Biotechnology Limited (AVEFF) reported $677K in revenue for Q4 2025, reflecting 21.0% growth compared to the prior quarter. The company recorded a net loss of $1.7M, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, AVEFF averaged $-0.00 in diluted EPS.
How Avecho Biotechnology Limited Is Valued
Avecho Biotechnology Limited carries a market capitalization of $10.68M, placing it in the micro-cap category. Relative to its peer group, AVEFF's quantitative score of 51/100 is below the peer average of 79/100.
Key Financial Metrics
Return on assets is -62.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Avecho Biotechnology Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -48.82 places it in the distress zone, a signal of elevated financial risk.
AVEFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Avecho's management showing confidence with recent insider buys could signal positive developments ahead. It's like when Musk was buying Tesla shares in 2020, it got everyone hyped.
- The community's buzzing about Avecho's potential in drug delivery - that kind of positive sentiment can really drive momentum. Think of the early days of CRISPR stocks.
- Avecho's focus on improving existing drugs could be a smart move, reducing risk compared to brand new therapies. It's a 'better mousetrap' strategy.
- Positive chatter about potential partnerships suggests Avecho might be gaining industry recognition, similar to what we saw with BioNTech before the Pfizer deal.
Bear Case
- Recent community grumbling about lack of news flow could indicate impatience and a potential sell-off. Remember the dot-com bubble? Hype needs substance.
- Insider activity, while positive, might not be enough to offset broader market concerns. It's like Lehman Brothers execs buying their own stock before the crash - didn't help much.
- The 'better mousetrap' approach might limit Avecho's upside compared to companies chasing groundbreaking innovations. It's a safe play, but maybe not a home run.
- Bearish sentiment highlighting regulatory hurdles could dampen enthusiasm. The FDA can be a real buzzkill, just ask any biotech company with a CRL.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $677,425 | -$2M | $0.0004 |
| Q2 2025 | $560,069 | -$3M | -$0.0008 |
| Q4 2024 | $820,484 | -$946,000 | -$0.0002 |
| Q2 2024 | $312,188 | -$2M | -$0.0006 |
Based on FMP financials and quantitative analysis
AVEFF Latest News
No recent news available for AVEFF.
AVEFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVEFF.
Price Targets
Wall Street price target analysis for AVEFF.
AVEFF MoonshotScore
What does this score mean?
The MoonshotScore rates AVEFF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul Gavin
CEO
Paul Gavin has extensive experience in the biotechnology sector, having held various leadership roles in both public and private companies. He possesses a strong background in drug development and commercialization, with a focus on innovative healthcare solutions. Gavin holds a degree in biochemistry and has been instrumental in driving Avecho's strategic direction since taking the helm.
Track Record: Under Paul Gavin's leadership, Avecho has successfully transitioned from Phosphagenics Limited to a focused biotechnology company, enhancing its product offerings and expanding its research collaborations. His strategic decisions have positioned the company for future growth in the competitive biotechnology landscape.
AVEFF OTC Market Information
The OTC Other tier is a classification for stocks that do not meet the criteria for the higher tiers of OTC markets, such as OTCQX or OTCQB. These stocks may have less stringent reporting requirements and can be less liquid, making them riskier for investors. Companies in this tier may not provide regular financial updates, leading to increased uncertainty in investment decisions.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may hinder investor confidence.
- Lower liquidity can lead to increased volatility in stock price.
- Potential regulatory challenges in the biotechnology sector.
- Review available financial reports and disclosures.
- Assess the company's product pipeline and research collaborations.
- Evaluate the competitive landscape and market trends.
- Monitor any regulatory developments affecting the biotechnology sector.
- Consider the company's operational capacity and employee base.
- Established history since 1992 and rebranding to Avecho Biotechnology Limited.
- Collaborations with reputable institutions like the University of Sydney.
- Proprietary technology with potential for significant market impact.
Common Questions About AVEFF (Healthcare)
What does Avecho Biotechnology Limited do?
Avecho Biotechnology Limited specializes in developing innovative drug delivery systems using its proprietary Targeted Penetration Matrix (TPM) technology. The company focuses on enhancing the efficacy of pharmaceutical products through various delivery methods, including gels and patches. Additionally, Avecho offers products for the skincare and animal health sectors, aiming to improve health outcomes across multiple industries.
What are the main risks for AVEFF?
Avecho Biotechnology Limited faces several risks, including regulatory challenges that could hinder the approval process for its products. The company also has a negative profit margin, which may indicate financial instability and affect its operational capabilities. Furthermore, competition from larger biotechnology firms poses a threat to Avecho's market share and growth potential, necessitating careful strategic planning to mitigate these risks.
What is Avecho Biotechnology Limited's drug pipeline status?
Avecho Biotechnology Limited is actively developing its drug pipeline, focusing on products such as TPM/Oxymorphone and TPM/Oxycodone. The company is also collaborating with the Lambert Initiative at the University of Sydney to explore the therapeutic potential of cannabidiol for osteoarthritis. These initiatives highlight Avecho's commitment to innovation and its strategic approach to addressing unmet medical needs in the healthcare sector.
What are the key factors to evaluate for AVEFF?
Avecho Biotechnology Limited (AVEFF) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does AVEFF data refresh on this page?
AVEFF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AVEFF's recent stock price performance?
Avecho Biotechnology Limited (AVEFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug delivery technology enhances product efficacy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AVEFF overvalued or undervalued right now?
Valuing Avecho Biotechnology Limited (AVEFF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AVEFF?
Before investing in Avecho Biotechnology Limited (AVEFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial stability is uncertain due to negative profit margins.